Lonza, Sartorius, and FUJIFILM Diosynth Bolster Biopharmaceutical Manufacturing Capacity, Highlighting Single-Use Technology as Key

SNS Insider Unknown

Overview

This article highlights the biopharmaceutical manufacturing capacity expansions by Lonza Group, Sartorius, and FUJIFILM Diosynth Biotechnologies, as noted in the “Biopharmaceutical Fermentation Market” report. Lonza expanded its manufacturing capacity in 2026, maintaining robust growth in its contract manufacturing business. Sartorius strengthened its portfolio with new single-use bioreactor technology and increased manufacturing capacity. FUJIFILM Diosynth enhanced its cell culture manufacturing capabilities by adding an extra 2,000 liters of single-use capacity. These expansions are strategic moves to meet the growing demand for biopharmaceuticals, improving manufacturing efficiency and flexibility.

In Depth

Key Findings: Lonza, Sartorius, and FUJIFILM Diosynth Strengthen Biopharmaceutical Manufacturing Capabilities, Single-Use Technology Pivotal for Efficiency

This article provides an update on the biopharmaceutical manufacturing capacity expansions by key players such as Lonza Group, Sartorius, and FUJIFILM Diosynth Biotechnologies, as mentioned in a report on the “Biopharmaceutical Fermentation Market.” These companies are undertaking strategic investments and capacity enhancements to meet the escalating demand for biopharmaceuticals and to improve the efficiency and flexibility of their manufacturing processes.

Detailed Manufacturing Capacity Expansion by Company

• Lonza Group:
  • **Manufacturing Capacity Expansion:** Lonza expanded its biopharmaceutical manufacturing capacity in 2026. This move reinforces its ability to handle a wide range of biopharmaceutical pipelines and ensures robust growth in its Contract Development and Manufacturing Organization (CDMO) business.
  • **Market Position:** Lonza further solidifies its position as a global leader in the contract development and manufacturing of complex biopharmaceuticals.
• Sartorius:
  • **Enhanced Bioprocessing Portfolio:** Sartorius has expanded its bioprocessing product and service portfolio through the introduction of new single-use bioreactor technology and an increase in manufacturing capacity.
  • **Benefits of Single-Use Technology:** Single-use systems eliminate the need for cleaning and sterilization, allowing for rapid changeovers, significantly enhancing manufacturing flexibility and cost-efficiency.
• FUJIFILM Diosynth Biotechnologies:
  • **Strengthened Cell Culture Manufacturing Capacity:** The company significantly boosted its cell culture manufacturing capabilities by incorporating an additional 2,000 liters of single-use bioreactor capacity.
  • **Purpose of Expansion:** This expansion is specifically aimed at addressing the increasing demand for large-scale manufacturing of monoclonal antibodies and gene therapies, balancing rapid supply with consistent quality for its clients.

Background & Context

The biopharmaceutical market is expanding rapidly, driven by the emergence of innovative therapies addressing unmet medical needs. This growth necessitates increasingly complex manufacturing processes, making efficient and scalable production capabilities indispensable. Single-use technology, in particular, is becoming a mainstream choice in biopharmaceutical manufacturing due to its advantages such as reduced capital investment, lower operational costs, and minimized risk of cross-contamination. The aggressive capacity expansions by these leading companies are crucial for enhancing overall industry productivity and, ultimately, improving patient access to critical medicines.

Strategic Significance & Outlook

These strategic investments by Lonza, Sartorius, and FUJIFILM Diosynth Biotechnologies are expected to further accelerate the growth of the biopharmaceutical manufacturing market. The focus on single-use technology will be a key driver in supporting the rapid development and commercialization of next-generation biopharmaceuticals, increasing market flexibility and responsiveness. Investors will likely view these companies’ commitments to manufacturing capacity and technological innovation as indicators of long-term growth and competitive advantage, promising more timely delivery of innovative therapies to patients.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime